Table 4

The use of topical medications and their alterations in patients with uveitis during the COVID-19 pandemic

AgentNumber of eyes receiving treatment (ongoing)
Number of eyes in whom frequency of drops was altered
(increased*, initiated†)
Betamethasone 1%3120*, 9†
Dexamethasone 0.1%208*, 3†
Prednisolone acetate 1%228* 3†
Flurbiprofen 0.3%194*
Ketorolac 0.5%53*
Nepafenac 0.1%20
Atropine 1%4212*
Homatropine 2%344* 3†
  • *Indicates the patients in whom the frequency of topical medications were increased from existing therapy.

  • †Indicates the patients in whom new treatments were started.